系统性红斑狼疮患者抗β_2糖蛋白Ⅰ抗体检测的意义

目的探讨系统性红斑狼疮(SLE)患者血清抗β2糖蛋白I(β2GPI)抗体检测的临床意义。方法采用酶联免疫吸附试验(ELISA)半定量测定56例SLE患者及40名健康对照者血清抗β2GPI和抗心磷脂抗体(ACA)阳性率。结果SLE患者血清抗β2GPI和ACA阳性率分别为69.6%、80.4%,明显高于正常对照(P<0.01);SLE伴有血栓栓塞症状或病史者抗β2GPI为94.1%,高于无血栓栓塞症状的SLE患者(P<0.01)。结论SLE患者抗β2GPI的高表达与其临床症状,尤其是血栓栓塞症状具有一定的相关性。     

脑梗死患者血清抗心磷脂抗体及 β2糖蛋白Ⅰ抗体水平及其临床意义

目的研究脑梗死患者血清抗心磷脂抗体(ACA)及β2糖蛋白Ⅰ抗体水平及其临床意义。方法选取2017年1月至2018年10月,到北京丰台右安门医院进行治疗的122例脑梗死患者,同时,选取68例同期到我院进行健康体检者作为对照组,所有受检者均进行ACA-IgG、ACA-IgM、β2 GPⅠ水平检测。结果脑梗死组患者β2GPⅠ[(3.05±1.02)μg/ml]、ACA-IgG[(3.43±1.77)mmol/L]、ACA-IgM[(3.41±1.75)μg/ml]水平均高于健康对照组[(1.64±0.75)μg/ml、(1.90±0.92) mmol/L、(1.89±1.30)μg/ml],差异有统计学意义(P0.05)。脑梗死组患者中,β2 GPⅠ阳性患者的总胆固醇、低密度胆固醇水平均明显高于阴性组,颈动脉狭窄、颈动脉斑块、颈动脉内膜增厚比例高于阴性组(P0.05),ACA-IgG阳性患者复发率高于阴性患者(P0.05)。结论脑梗死患者ACA、β2 GPⅠ抗体水平明显上升,对病情判断及复发预测均具有重要意义。     

系统性红斑狼疮患者血清抗β2糖蛋白Ⅰ抗体与抗心磷脂抗体亚型水平及关系

目的：采用间接ELISA法对41例系统性红斑狼疮（SLE）患者的血清进行了抗β2糖蛋白Ⅰ（β2GPⅠ）抗体及抗心磷脂抗体亚型进行测定并相互比较，分析其在APS—SLE中可能的临床意义，探讨SLE患者抗β2GPⅠ抗体及抗心磷脂抗体亚型与血脂水平和凝血酶原时间之间的关系。方法：采集2006年8月至2007年1月温州医学院附属第一医院收治的SLE患者血液标本41例，采用ELISA法测定血清中ACA及aβ2GPⅠ水平，同时检测ds-DNA抗体、TG、CH、APTT、PT等相关指标。结果：①41例SLE患者中aβ2GPⅠ升高者10例（24．4％），ACA-IgG阳性者20例（48．8％），ACA-IgA阳性者7例（17．1％）与正常对照组比较差异均有显著性意义（P分别〈0．001或〈0．05）；②10例aβ2GPⅠ阳性SLE患者中有4例同时存在ACA阳性，其中3例为同时ACA-IgG、ACA-IgA阳性，1例为ACA-IgG阳性。41例SLE患者aβ2GPⅠ阳性率与ACA-IgG、ACA-IgA间差异无显著性意义（P均〉0．05）；③伴有继发性磷脂综合征的SLE和无继发性磷脂综合征SLE患者相关指标的比较，差异均无显著性意义（P均〉0．05）；①41例SLE患者ds-DNA抗体、TG、CH、APTT、PT与抗β2GPⅠ抗体和ACA亚型进行相关性分析，结果CH与ACA-IgA存在正相关，r=0．66，p〈0．05；APTT与ACA-IgG存在负相关，r=-0．313，p〈0．05。结论：结果提示抗β2GPⅠ抗体可作为SLE继发APS的诊断指标，但若联合ACA检测将会提高检出率从而降低漏诊率；虽然ACA-IgG的存在将会导致凝血瀑布反应，使机体处于高凝状态；及ACA-IgA可能与其靶抗原β2GPⅠ结合，造成胆固醇堆积；或β2GPⅠ发挥其天然抗凝作用，但抗β2GPⅠ抗体和ACA水平与SLE活动性无关，同时SLE患者是否继发抗磷脂综合征与血脂水平和凝血酶原时间无关。     

β2糖蛋白Ⅰ、抗β2糖蛋白Ⅰ抗体与抗磷脂综合征

β2糖蛋白Ⅰ(β2-glycoproteinⅠ,β2GPⅠ)作为抗磷脂抗体(antiphospholipid antibody,aPL)的主要靶抗原,在抗磷脂综合征(antiphospholipid syndrome,APS)的血栓形成过程中发挥重要作用。虽然抗β2GPⅠ抗体较抗心磷脂抗体(anticardiolipinantibody,aCL)对APS的诊断具有更高的特异性,但抗β2GPⅠ抗体与抗心磷脂抗体联合检测更利于APS的诊断。本文对β2GPⅠ的结构、生理功能及其与抗β2GPⅠ抗体的结合、抗β2GPⅠ抗体诱发血栓形成的机制等方面进行较详细的阐述。APS是在1985年被正式命名的一种非器     

系统性红斑狼疮患者抗β2糖蛋白I抗体检测的意义

目的探讨系统性红斑狼疮（SLE）患者血清抗β2糖蛋白Ⅰ（β2GPI）抗体检测的临床意义。方法采用酶联免疫吸附试验（ELISA）半定量测定56例SLE患者及40名健康对照者血清抗β2GPI和抗心磷脂抗体（ACA）阳性率。结果SLE患者血清抗β2GPI和ACA阳性率分别为69．6％、80．4％，明显高于正常对照（P〈0．01）；SLE伴有血栓栓塞症状或病史者抗β2GPI为94．1％，高于无血栓栓塞症状的SLE患者（P〈0．01）。结论SLE患者抗β2GPI的高表达与其临床症状，尤其是血栓栓塞症状具有一定的相关性。     

抗β2-糖蛋白Ⅰ抗体与先兆流产的关系

目的探讨抗β2-糖蛋白Ⅰ抗体与先兆流产的关系。方法通过酶联免疫吸附试验（ELISA）检测121例先兆流产孕妇（其中妊娠未成功者75例,妊娠成功者46例）、40名健康正常妇女（其中未妊娠者20名,妊娠者20名）的血清中抗β2-糖蛋白Ⅰ抗体（IgM型）的水平。结果先兆流产组血清抗β2-糖蛋白Ⅰ抗体总阳性率为58.7%,与对照组（17.5%）相比,差异有统计学意义（P〈0.05）。妊娠未成功组阳性率为78.7%,与妊娠成功组（26.1%）比较,差异有统计学意义（P〈0.05）;妊娠未成功组与对照组比较,差异有统计学意义（P〈0.05）,而妊娠成功组与对照组相比,差异无统计学意义（P〉0.05）;首次先兆流产组、多次先兆流产组抗β2-糖蛋白Ⅰ抗体阳性率均高于健康正常妊娠组（P〈0.05）,而不同次数先兆流产组间阳性率差异无统计学意义（P〉0.05）。结论先兆流产与体内抗β2-糖蛋白Ⅰ抗体的存在有关,检测抗β2-糖蛋白Ⅰ抗体可为先兆流产的诊断、治疗及预后判断提供实验室依据。     

β2GPⅠ及其抗体与抗磷脂综合征的研究进展

抗磷脂综合征(APS)是一种以血栓形成和(或)习惯性流产为临床特征的自身免疫性疾病。β2糖蛋白Ⅰ(β2GPⅠ)是该病的主要抗原,抗β2GPⅠ抗体是以β2GPⅠ为靶抗原的自身抗体。研究表明,β2GPⅠ及其自身抗体在APS血栓形成的致病过程中起到重要作用。目前APS的诊断与治疗也越来越受到人们的重视,检测抗β2GPⅠDⅠ抗体能特异性诊断APS,分子水平的研究也成为治疗APS的新方向。该文就β2GPⅠ、抗β2GPⅠ抗体与APS的相关性进展作以综述。     

系统性红斑狼疮患者抗β2糖蛋白I抗体检测的意义

目的 探讨系统性红斑狼疮(SLE)患者血清抗β2糖蛋白I(β2GPI)抗体检测的临床意义.方法 采用酶联免疫吸附试验(ELISA)半定量测定56例SLE患者及40名健康对照者血清抗β2GPI和抗心磷脂抗体(ACA)阳性率.结果 SLE患者血清抗β2GPI和ACA阳性率分别为69.6%、80.4%,明显高于正常对照(P＜0.01);SLE伴有血栓栓塞症状或病史者抗β2GPI为94.1%,高于无血栓栓塞症状的SLE患者(P＜0.01).结论 SLE患者抗β2GPI的高表达与其临床症状,尤其是血栓栓塞症状具有一定的相关性.     

β2-糖蛋白Ⅰ的多重作用及其抗体在血液系统疾病中的研究进展

β2-糖蛋白Ⅰ(β2-GPⅠ)是一种具有双重调节补体系统和凝血系统的功能蛋白。β2-GPⅠ不仅具有抗凝、抗血小板和促凝作用,还具有调节补体、调节血管生成及调节免疫的作用。近些年新方法的应用不仅提升了β2-GPⅠ分离纯化的能力,更进一步提升了抗β2-GPⅠ抗体的检测灵敏度及特异性。在临床上,β2-GPⅠ及其抗体可能参与了免疫性血小板减少症、白血病、淋巴瘤等多种血液系统疾病的发生发展。该文综述了β2-GPⅠ的作用、相关指标检测方法、β2-GPⅠ及其抗体在血液系统疾病中的研究进展。     

脑梗死患者与血清抗心磷脂抗体及β2糖蛋白Ⅰ抗体的关系研究

目的探讨复发性、首发性脑梗死患者血淸抗心磷脂(ACA)抗体(ACA-IgG、IgM)、β2糖蛋白Ⅰ(β2GPⅠ)的关系,为脑梗死患者的预防和治疗提供依据。方法 ELISA法定量检测230例首发性脑梗死、264例复发性脑梗死、145例健康对照者血清ACA-IgG、ACA-IgM、β2GPⅠ,对比分析各组别之间的差异。结果经方差分析,首发性脑梗死组、复发性脑梗死组、健康对照组血清抗心磷脂抗体ACA-IgG、ACA-IgM、β2GPⅠ水平差异有统计学意义(P0.05),首发性脑梗死组、复发性脑梗死组均高于健康对照组,差异有统计学意义(P0.05),复发性脑梗死组高于首发脑梗死组,差异有统计学意义(P0.05)。结论检测脑梗死患者的血清ACA、β2GPⅠ对于脑梗死的复发预测和临床早期干预有重要的意义。     

Occurrence of anti-prothrombin and anti-beta2-glycoprotein I antibodies in patients with history of thrombosis

New evidence indicates that antibodies to beta2-glycoprotein I (anti-beta2GPI) or to human prothrombin (anti-II)(or to both of these) are specific markers of the antiphospholipid syndrome (APS). They have been mainly associated with thrombotic complications in patients with APS. However, some studies have reported that elevated levels of anti-II, but not of anfi-beta2GPI, imply a risk of venous thrombosis (VT) or arterial thrombosis (AT) in subjects with no previous thrombosis and no antiphospholipid antibodies (aPL) by ELISA. The present study Included 180 patients with a history of thrombosis, 83 of them without aPL (group I) and the remaining 97 diagnosed as having APS (group II). Anti-beta2GPI was found in only 1 of the 83 patients from group I but was found in approximately 50% of those from group II (P < .0001). In contrast, positive anti-II was detected with a high prevalence in patients from group I (VT, 22.6%; AT, 26.7%) and in those from group II (VT, 37.5%; AT, 14.6%). No statistical differences were found in the prevalence of anti-II between the two groups of patients. On the other hand, such a difference was significant when compared with results in a normal group (1/67, 1.4%, P < .0001). These data Indicate that anti-II occurs frequently in patients with previous thrombosis either with or without lupus anticoagulant activity. Accordingly, testing of anti-II might be clinically useful in the evaluation for thrombophilla.     

Beta-2-glycoprotein I antibodies in patients with thrombosis

The laboratory diagnosis of antiphospholipid antibody syndrome currently requires two consecutive positive results in either lupus anticoagulant or anticardiolipin antibody assays. Antibodies against beta-2-glycoprotein I (abeta2-GPI) are suggested as a new marker for the syndrome. The inclusion of abeta2-GPI in the official diagnostic criteria has so far been precluded owing to lack of an international standard and also technical difficulties. Samples from 5367 consecutive patients sent to a national reference laboratory mainly because of various thrombotic events were studied. An IgG abeta2-GPI ELISA assay was performed in addition to lupus anticoagulant (dRVVT and PTT-LA) and IgG anticardiolipin antibody determinations to evaluate patient groups in which the new assay might be of value. From a total of 90 patients, 2.2% of the samples were abeta2-GPI positive; 51 patients had abeta2-GPI as the only positive antiphospholipid antibody marker; 20 patients had had a venous thrombosis and 14 an arterial thrombosis, 4 had pregnancy complications and 2 had thrombocytopenia. Relatively young patients with cerebrovascular ischaemic events seemed especially to present sole abeta2-GPI positivity. The abeta2-GPI positivity remained fairly constant in the 23 patients from whom follow-up samples were taken. It is concluded that the IgG abeta2-GPI assay seems to be a potentially important additional diagnostic tool for the antiphospholipid antibody syndrome.     

Combined search for anti-beta2-glycoprotein I and anticardiolipin antibodies in antiphospholipid syndrome: contribution to diagnosis

In this study we sought to assess (1) the diagnostic value of a combined search for anti-beta(2)-glycoprotein (abeta(2)-GPIs) and anticardiolipin antibodies (aCLs) in primary (APS I) and secondary (APS II) antiphospholipid syndrome and (2) the influence of the beta(2)-GPI preparation in the ELISA's results. abeta(2)-GPI and aCL concentrations were assessed in 70 patients with APS and compared with those in 65 patients with systemic lupus erythematosus (SLE) without clinical features of APS. In APS patients (38 with APS I, 32 with APS II), the diagnosis had to have been made at least 3 years earlier; in subjects with SLE, the diagnosis had to have been made at least 5 years earlier. All serum samples were tested for abeta(2) -GPI with the use of an in-house ELISA with an abeta(2) -GPI preparation from human plasma. Samples negative for abeta(2) -GPI were controlled with 2 additional beta(2)-GPI preparations, 1 from human serum and 1 from bovine serum. In APS, abeta(2)-GPIs were more frequent than in SLE (76% and 15%, respectively; P <.0001), mainly with IgG isotype and with significantly higher levels than those found in SLE. The specificity for APS was 92% for IgG abeta(2)-GPIs and 68% for IgG aCLs. The highest association with APS was found for the combination of the 2 markers (odds ratio 29; 95% confidence interval 10-76; P <.0001). Among the APS patients, 6 were positive for aCL only and remained negative regardless of which beta 2 -GPI preparation was used; 1 patient was aCL-negative and only positive with human beta 2 -GPI. These data emphasize the heterogeneity of the APS immunologic profile and the diagnostic possibilities of both antibodies.     

Antiphosphatidylserine antibodies in patients with autoimmune diseases and HIV-infected patients: effects of Tween 20 and relationship with antibodies to beta2-glycoprotein I

Antiphospholipid antibodies (aPL) react with negatively charged phospholipids, which may often be complexed with a protein cofactor such as beta2 glycoprotein (beta2GPI) and prothrombin. Cofactor requirements may be assessed by measuring antibodies to beta2GPI or by adding Tween 20 to some reagents in the assays for aPL (anticardiolipin and antiphosphatidyIserine). We have measured anticardiolipin antibodies (aCL), antiphosphatidylserine antibodies (aPS), and anti beta2 glycoprotein antibodies (abeta2GPI) in the serum of 10 normal subjects, 20 patients with systemic autoimmune diseases (SAD) diagnosed as having systemic lupus erythematosus (SLE) or antiphospholipid syndrome (APS), and 12 patients with HIV infection. Adding Tween 20 to aPS, the assay couldn't differentiate protein cofactor dependent from independent antibodies, but this can be done by measuring abeta2GPI (P= 0.0008). There was a significant correlation between aCL and a(beta)2GPI in the control group and in the patients with SAD, but not in the HIV-positive (HIV+) patients.After excluding the HIV+ patients, the best Spearman correlation was obtained between a(beta)2GPI and aCL (0.64, P< 0.0005). In 3 out of 7 patients with positive a(beta)2GPI and in 5 out of 6 patients with moderate or high positive aCL of the group of SAD, there was a history of venous thrombosis. The presence of moderate or high values of aCL either alone or together with a(beta)2GPI was significantly associated with a history of venous thrombosis (P < 0.05). Moderate or high aCL concentrations and their association with a(beta)2GPI seems to be useful for the assessment of the risk of venous thrombosis in unselected patients with SLE or APS.